Intero Biosystems Wins TechCrunch Disrupt 2026 Startup Battlefield, Secures $100,000 Prize
Intero Biosystems has won TechCrunch Startup Battlefield 2026, earning recognition for its innovative approach to drug testing using lab-grown human intestinal tissue. The Denver-based biotech startup emerged as the winner of the high-profile startup competition at TechCrunch Disrupt 2026 in San Francisco on October 15. Founded by Charlie Childs and Madeline Eiken, Intero Biosystems is developing technology designed to help pharmaceutical and biotechnology companies study how drugs and other compounds affect the human body before testing them in people. The win puts the early-stage company in the spotlight as investors increasingly look toward biotechnology, life sciences and technologies that could transform drug development. <Cite refs={[“turn645196news0″,”turn645196news1”]}/> What Is Intero Biosystems? Intero Biosystems is building miniature human intestinal organoids, which are lab-grown tissues designed to mimic important characteristics of the human gut. Its flagship product, GastroScreen, allows pharmaceutical, biotech, food and chemical companies to evaluate how different compounds interact with intestinal tissue. Each organoid measures approximately one millimeter across. Unlike simpler laboratory models that reproduce only parts of the intestine, Intero’s approach incorporates multiple cell and tissue types found in the human gut. The technology could give researchers another tool for studying drug responses and evaluating compounds during early-stage development. It may also help address some limitations of traditional testing methods, although its effectiveness depends on the specific application and further validation. Why Did Intero Biosystems Win Startup Battlefield 2026? TechCrunch Disrupt’s Startup Battlefield brings promising early-stage companies before investors, industry experts and technology leaders. This year’s competition featured 20 startups selected from the broader Startup Battlefield 200 program. After live demonstrations and judging, five finalists advanced to the final round: Intero Biosystems, Apate, Flox Intelligence, Industrial Next and Satlyt. Intero ultimately claimed the Startup Battlefield Cup and the $100,000 equity-free prize, giving the company both financial support and visibility among the startup and venture capital communities. <Cite refs={[“turn645196news0″,”turn645196search10”]}/> The competition highlights how emerging companies are tackling problems across healthcare, cybersecurity, industrial automation and space technology. How Human Organoids Could Change Drug Development Drug developers often rely on laboratory experiments and animal models to evaluate potential treatments. However, biological differences between animals and humans can make it difficult to predict how a drug will behave in people. Human intestinal organoids offer an additional research model that more closely reflects aspects of human biology. Intero’s GastroScreen platform aims to help researchers examine how compounds affect intestinal tissue before advancing their development. Such models could support early research, help identify potential problems and provide additional information when evaluating candidate drugs. However, organoids are not complete replacements for clinical trials or every existing testing method. Researchers must assess each model’s reliability and suitability for its intended use. What the Win Means for the Biotech Startup Winning Startup Battlefield gives Intero Biosystems a prominent platform to introduce its technology to potential investors, customers and industry partners. The company spun out of the University of Michigan, combining scientific research with a commercial product aimed at pharmaceutical and other industries. Its victory also reflects growing interest in technologies that make drug development more human-relevant and potentially reduce dependence on animal testing where validated alternatives are appropriate. For the broader startup ecosystem, Intero’s success demonstrates how scientific innovation can become a commercial opportunity when founders address a clear industry challenge. The bottom line: Intero Biosystems’ Startup Battlefield 2026 victory puts its human intestinal organoid technology on the map. Its next challenge will be demonstrating the value of GastroScreen in real-world research and expanding adoption among pharmaceutical and biotechnology customers.Source: TechCrunch










